

سرطانات الدم النخاعية الناتجة عن العلاج الكيميائى

رسالة مقدمة توطئة للحصول

على درجة الماجستير

فى الباثولوجيا الاكلينيكية و الكيمائية

من

الطبيبة/ رندا أمين عثمان

بكالوريوس الطب و الجراحة

تحت اشراف

أ.د. تيسير كامل عيادة

أستاذ الباثولوجيا الاكلينيكية و الكيمائية

كلية الطب – جامعة القاهرة

د. بسمة مصطفى الجمل

أستاذ مساعد الباثولوجيا الاكلينيكية و الكيمائية

المعهد القومى للأورام – جامعة القاهرة

كلية الطب

جامعة القاهرة

2010

Therapy-Related Myeloid Neoplasms

Essay

Submitted for partial fulfillment of

Master degree in Clinical and Chemical pathology

By

Randa Amin Osman

(M.B.,B.CH.Cairo University)

Supervised by

Prof. Tayssir Kamel Eyada

Professor of clinical&chemical pathology

Faculty of Medicine, Cairo University

Dr. Basma Mostafa Al Gamal

Assistant Professor of clinical &chemical pathology

National Cancer Institute, Cairo University

Faculty of Medicine

Cairo University

2010

*INTRODUCTION AND
AIM THE OF WORK*

SUMMARY

الملخص العربي

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

"قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا

إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ"

سورة البقرة، آية (32)

Acknowledgement

My sincere appreciation is to my professor **Dr.Tayssir Kamel Eyada**, Professor of clinical&chemical pathology, Faculty of Medicine, Cairo University, for providing me with her valuable advice and experience.

I would like also to express my deep gratitude to **Dr. Basma Mostafa AlGamal**, Assistant Professor of clinical &chemical pathology, National Cancer Institutet , Cairo University, for her generous care and outstanding support she gave me to accomplish this work.

To *my family*, my profound love and appreciation for all what they have done for me to be what I am.

Review of literature

REFERENCES

CHAPTER I

Classification & incidence of therapy-related myeloid neoplasms

CHAPTER II

Etiology & pathogenesis of therapy-related myeloid neoplasms

CHAPTER III

Management of therapy-related myeloid neoplasms

Abstract:

Therapy-related myeloid neoplasms (t-MN) is the term proposed by the 2008 W.H.O classification to cover the spectrum of malignant disorders previously described as therapy-related myelodysplastic syndrome(t-MDS) or therapy-related acute myeloid leukemia (t-AML) which occur as a late complication following cytotoxic therapy by alkylating agents,topoisomerase-II inhibitors &immunosuppressants. Eight genetic pathways are involved in the pathogenesis leading to chromosomal deletion,gain or translocation. It is generally a fatal disease with poor survival. Allogenic haemopoietic cell transplantation is the most likely treatment.

Table of contents

Item	Page
❖ List of Abbreviations	i
❖ List of Figures	vii
❖ List of Tables	viii
❖ Introduction & Aim of the work	1
❖ Review of literature	
• Chapter I:classification & incidence of t-MN:	
Introduction	5
Acute myeloid leukemia and related precursor neoplasms	7
Significant changes in the diagnosis and classification of AML and related precursor neoplasms	17
Epidemiology of t-MDS/AML	20
Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma	29
Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia	31
The <i>NQO1</i> C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia	33

Risk Factors for Leukemia and Myelodysplastic Syndrome After Breast Cancer	36
Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma	40
AML in recipients of transplants	44
• Chapter II: Etiology & pathogenesis of t-MN:	
Introduction	47
Genetic Pathways in t-MDS and t-AML	50
Predisposing factors of therapy-related myeloid neoplasms	53
Tumor Suppressors and Oncogenes	69
Etiological factors of t-MN	
I-Alkylating agents	76
II-Topoisomerase II inhibitors	89
III-Immunosuppressants	103
IV-Granulocyte-colony stimulating factor	123
V-High dose chemotherapy & autologous bone marrow transplantation	125
• Chapter III: Management of t-MN:	
Diagnosis of therapy-related myeloid leukemia	132
Prognosis of therapy-related myeloid leukemia	144
Treatment of therapy-related myeloid leukemia	150